APA (7th ed.) Citation

Oza, A. M., Matulonis, U. A., Malander, S., Hudgens, S., Sehouli, J., del Campo, J. M., . . . Mirza, M. R. (2018). Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): Results from a double-blind, phase 3, randomised controlled trial. Lancet Oncology, 19(8), 1117. https://doi.org/10.1016/S1470-2045(18)30333-4

Chicago Style (17th ed.) Citation

Oza, Amit M., et al. "Quality of Life in Patients with Recurrent Ovarian Cancer Treated with Niraparib Versus Placebo (ENGOT-OV16/NOVA): Results from a Double-blind, Phase 3, Randomised Controlled Trial." Lancet Oncology 19, no. 8 (2018): 1117. https://doi.org/10.1016/S1470-2045(18)30333-4.

MLA (9th ed.) Citation

Oza, Amit M., et al. "Quality of Life in Patients with Recurrent Ovarian Cancer Treated with Niraparib Versus Placebo (ENGOT-OV16/NOVA): Results from a Double-blind, Phase 3, Randomised Controlled Trial." Lancet Oncology, vol. 19, no. 8, 2018, p. 1117, https://doi.org/10.1016/S1470-2045(18)30333-4.